Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Improving Outcomes in Hodgkin Lymphoma

Access Activity

Overview / Abstract:

This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Start the activity now.


Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed each year in the United States (Siegel et al, 2021). While the advent of novel therapies is leading to significantly improved outcomes, HL treatment continues to be associated with an increased risk for secondary cancers and cardiovascular disease(NCCN, 2021; Kreissl et al, 2020). In order to minimize long-term treatment effects and maximize health-related quality of life for patients with HL, clinicians need to stay abreast of newly established recommendations and evolving data. In this activity, Louis F. Diehl, MD, will update clinicians on developing evidence-based HL management plans tailored to individual patients and their long-term care needs.


Hematologist/oncologists, hematology/oncology fellows, nurse practitioners, physician assistants, pharmacists, oncology nurses, and other health care professionals involved in the treatment of patients with hematologic malignancies.


Discuss predictive and prognostic markers that can individualize treatment selection for patients with HL
Assess emerging efficacy and safety data on novel therapeutic strategies for HL
Evaluate strategies to optimize the safety and tolerability of novel therapies for HL


Feb 14, 2023


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours

1.0 CME | 1.0 NPCD | 1.0 CPE | MOC | ILNA



Presenters / Authors / Faculty

Louis Diehl, MD
Professor of Medicine
Duke University School of Medicine

Activity Specialities / Related Topics

Hematology, Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from BeiGene, Bristol Myers Squibb, Merck, and Seagen.

Keywords / Search Terms

i3 Health i3 Health i3 Health i3 health,hodgkin lymphoma,hematology, rare hematology, CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD, CME ,Free CE CME, Free CE CME, ANCC Free CE CME Free CE CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map